Monoclonal Antibodies in the Treatment of Transplant Rejection

1989 ◽  
pp. 325-344
Author(s):  
David J. Cohen
Keyword(s):  
Monoclonal Antibodies ◽  
Transplant Rejection

scholarly journals Monoclonal Antibodies: A Tool in Clinical Research

2013 ◽  
Vol 4 ◽  
pp. IJCM.S11968 ◽  
Author(s):  
Waliza Ansar ◽  
Shyamasree Ghosh
Keyword(s):  
Monoclonal Antibodies ◽  
Clinical Medicine ◽  
Future Prospect ◽  
Transplant Rejection ◽  
Antibody Engineering ◽  
West Germany ◽  
Pharmaceutical Application ◽  
Pharmaceutical Applications ◽  
Hybridoma Technology ◽  
Applied Biology

Monoclonal antibodies (MAbs) are an old immunological tool with applications in the fields of immunology, biotechnology, biochemistry, and applied biology. Production of monoclonal antibodies using hybridoma technology was discovered in 1975 by Georges Kohler of West Germany and Cesar Milstein of Argentina. Modern-day research on MAbs from laboratories worldwide is revealing additional applications in diverse branches of sciences. Recently, MAbs have been widely applied in the field of clinical medicine. Currently, MAbs account for one-third of all the new therapeutic treatments for breast cancer, leukemia, arthritis, transplant rejection, asthma, and psoriasis, with many more late-stage clinical trials being conducted. In this review, we outline the (i) production of MAbs, (ii) application of MAbs, (iii) antibody engineering, and (iv) pharmaceutical application of MAbs. The future prospect of this review lies in the applicability of monoclonal antibodies as a molecule for understanding and monitoring the biology of disease and its role in research, clinical, diagnostic, analytical, and pharmaceutical applications.

Blocking of Costimulatory Pathways Using Monoclonal Antibodies as a New Strategy to Prevent Transplant Rejection in a Non-Human Primate Model

1998 ◽  
Vol 30 (4) ◽  
pp. 1061-1062 ◽  
Author(s):  
M.A Ossevoort ◽  
M de Boer ◽  
K Lorré ◽  
A Van de Voorde ◽  
M Jonker
Keyword(s):  
Monoclonal Antibodies ◽  
Transplant Rejection ◽  
Primate Model ◽  
New Strategy ◽  
Human Primate

Characterization of anti-canine cytokine monoclonal antibodies specific for IFN-γ: Effect of anti-IFN-γ on renal transplant rejection

1994 ◽  
Vol 43 (3) ◽  
pp. 163-169 ◽  
Author(s):  
Laphalle Fuller ◽  
Manuel Carreno ◽  
Violet Esquenazi ◽  
Keith Zucker ◽  
Shiyan Zheng ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Renal Transplant ◽  
Transplant Rejection ◽  
Ifn Γ ◽  
Renal Transplant Rejection

Immune checkpoint inhibitors in the management of malignancies in transplant recipients

2018 ◽  
Vol 94 (1118) ◽  
pp. 704-708 ◽  
Author(s):  
Dileep Kumar Reddy Regalla ◽  
Grant R Williams ◽  
Ravi kumar Paluri
Keyword(s):  
Monoclonal Antibodies ◽  
Cancer Immunotherapy ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Transplant Rejection ◽  
Treatment Strategies ◽  
Therapeutic Benefit ◽  
History Of ◽  
Active Research

Cancer immunotherapy, an area of active research, has thus far yielded several exciting breakthroughs in cancer treatment strategies. So far, immune checkpoint inhibitors have been the most promising method of cancer immunotherapy. CTLA-4, PD-1 and PD-L1 are the immune checkpoint molecules against which monoclonal antibodies act against and revolutionised the treatment of several malignancies. However, it is still unclear whether using these monoclonal antibodies in patients with malignancy and a history of transplant is as beneficial as in patients without a history of transplantation. The reason being, with the therapeutic benefit, also comes the inherent disadvantage of transplant rejection because of the activation of T-cells against donor antigens. So, transplant-related complications limit the usage of the checkpoint blockade therapy to treat malignancies. Here, we review the data published in this context and suggest optimal approaches to using the currently available repertoire of immunotherapies.

Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors

1995 ◽  
Vol 40 (1) ◽  
pp. 58-64 ◽  
Author(s):  
Maria-Luisa Alegre ◽  
Deborah J. Lenschow ◽  
Jeffrey A. Bluestone
Keyword(s):  
Monoclonal Antibodies ◽  
Transplant Rejection ◽  
Soluble Receptors

Ultrastructural analysis of unique glycoconjugates in the rat olfactory system

1992 ◽  
Vol 50 (1) ◽  
pp. 890-891
Author(s):  
James E. Crandall ◽  
Linda C. Hassinger ◽  
Gerald A. Schwarting
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Monoclonal Antibodies ◽  
Olfactory System ◽  
Olfactory Bulbs ◽  
Temporal And Spatial Patterns ◽  
Carbohydrate Epitopes ◽  
Olfactory Systems ◽  
Temporal And Spatial ◽  
Cell Surface Glycoconjugates

Cell surface glycoconjugates are considered to play important roles in cell-cell interactions in the developing central nervous system. We have previously described a group of monoclonal antibodies that recognize defined carbohydrate epitopes and reveal unique temporal and spatial patterns of immunoreactivity in the developing main and accessory olfactory systems in rats. Antibody CC2 reacts with complex α-galactosyl and α-fucosyl glycoproteins and glycolipids. Antibody CC1 reacts with terminal N-acetyl galactosamine residues of globoside-like glycolipids. Antibody 1B2 reacts with β-galactosyl glycolipids and glycoproteins. Our light microscopic data suggest that these antigens may be located on the surfaces of axons of the vomeronasal and olfactory nerves as well as on some of their target neurons in the main and accessory olfactory bulbs.

Structural and Chemical Studies of Pathological Fibers in Human Neurofibrillary Degeneration

1985 ◽  
Vol 43 ◽  
pp. 726-729
Author(s):  
K.S. Kosik ◽  
L.K. Duffy ◽  
S. Bakalis ◽  
C. Abraham ◽  
D.J. Selkoe
Keyword(s):  
Monoclonal Antibodies ◽  
Alzheimer Disease ◽  
Human Brain ◽  
Neurofibrillary Tangles ◽  
Morphological Analysis ◽  
High Specificity ◽  
Cytoskeletal Proteins ◽  
Neuritic Plaque ◽  
Protein Chemistry ◽  
Chemical Studies

The major structural lesions of the human brain during aging and in Alzheimer disease (AD) are the neurofibrillary tangles (NFT) and the senile (neuritic) plaque. Although these fibrous alterations have been recognized by light microscopists for almost a century, detailed biochemical and morphological analysis of the lesions has been undertaken only recently. Because the intraneuronal deposits in the NFT and the plaque neurites and the extraneuronal amyloid cores of the plaques have a filamentous ultrastructure, the neuronal cytoskeleton has played a prominent role in most pathogenetic hypotheses.The approach of our laboratory toward elucidating the origin of plaques and tangles in AD has been two-fold: the use of analytical protein chemistry to purify and then characterize the pathological fibers comprising the tangles and plaques, and the use of certain monoclonal antibodies to neuronal cytoskeletal proteins that, despite high specificity, cross-react with NFT and thus implicate epitopes of these proteins as constituents of the tangles.

Influence of mycophenolate mofetil on BTLA and ICOS signaling in renal transplant rejection

2010 ◽  
Vol 34 (8) ◽  
pp. S70-S70
Author(s):  
Yan Wang ◽  
Chuan Tian ◽  
Chun Mei Wang ◽  
Chun Guang Fan ◽  
Gang Liu
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Transplant ◽  
Transplant Rejection ◽  
Renal Transplant Rejection
Sign in / Sign up

Export Citation Format

Share Document